This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Expand Your Portfolio with this First Profit Stock Screener
by Benjamin Rains
We are in the midst of the fourth quarter earnings season. This makes it a great time to use our 'First Profit' stock screener. The idea is to search for companies that recently reported their first quarterly profit...
CRISPR Therapeutics AG (CRSP) Stock Moves -0.9%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $51.95 in the latest trading session, marking a -0.9% move from the prior day.
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
by Zacks Equity Research
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
SCANS: The FAANG of The Roaring 20s
by Daniel Laboe
A new acronym of equities that could define the next decade of investing.
The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk
SCANS: The FAANG Of The Roaring 20s
by Daniel Laboe
I have chosen a new acronym of stocks that I believe could change the world in the roaring 20s
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $59.44 in the latest trading session, marking a +0.2% move from the prior day.
What the Tech?
by Panel Of Zacks Experts
Let's REALLY dive deep into the abyss which can be tech. Associate Stock Strategist Dan Laboe, Zacks' resident Tech geek joins us.
Find Strong Stocks Heading into 2020 with this First Profit Screen
by Benjamin Rains
Wall Street has started to look ahead to 2020. So today we are going to use our 'First Profit' stock screen to help investors find strong stocks heading into the new year...
Trade of the 2020's: Sell Gold, Buy Biotech
by Kevin Cook
In 5 years, you be selling your gold and buying more companies leading the century of biology.
Biotech Tops in November: Best ETFs & Stocks
by Sweta Killa
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
Why Gold is Headed to Zero -- And What You Should Buy Instead
by Kevin Cook
In 2026, NASA mission Psyche will explore an asteroid that could hold over $5,000 quadrillion in gold
Why Biotech ETFs Surged in Monday's Trading Session
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.
Genomics ETFs Surge on CRISPR's Gene Editing Progress
by Sweta Jaiswal, FRM
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi
by Zacks Equity Research
The French reimbursement for Vertex's (VRTX) cystic fibrosis medicine Orkambi removes a key overhang for the stock.
Company News For Nov 20, 2019
by Zacks Equity Research
Companies in the news are: AMD, SAEX, DSS, CRSP
Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data
by Zacks Equity Research
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
by Zacks Equity Research
Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.
Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Vertex (VRTX) encourages investors with better-than-expected earnings in Q3. However, the top line misses the mark.
Investors Can Find Strong Stocks with our First Profit Screen
by Benjamin Rains
Today, we are utilizing our 'First Profit' stock screen to help investors find strong stocks. The idea is to search for companies that just reported their first quarterly profit within the last year...
CRISPR Therapeutics AG (CRSP) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 352.63% and 3252.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings?
by Zacks Equity Research
During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.